SimBioSys Introduces TumorSight Plan: Clinical Support for Early-Stage Breast Cancer

SimBioSys®, an innovative TechBio firm harnessing spatial biophysics with artificial intelligence (AI) and computational modeling to revolutionize precision medicine in cancer, is thrilled to unveil its latest clinical offering, TumorSight Plan. This groundbreaking application is the first of its kind,…

Read MoreSimBioSys Introduces TumorSight Plan: Clinical Support for Early-Stage Breast Cancer

Ferronova Initiates Nanoparticle Trial for Gastric & Esophageal Cancers

Australian biotech firm, Ferronova, has commenced a clinical trial featuring their FerroTrace® nanoparticle technology in individuals diagnosed with gastric and esophageal cancers. This trial follows the successful completion of a first-in-human trial conducted between 2020 and 2022, focusing on oral…

Read MoreFerronova Initiates Nanoparticle Trial for Gastric & Esophageal Cancers

Onchilles Pharma Unveils AACR 2024 Preclinical Data: Promising Treatment Potential

Onchilles Pharma, a pioneering biotech firm specializing in cancer treatments harnessing a unique innate immune approach for targeted and potent tumor eradication, revealed groundbreaking preclinical findings today. The data pertained to N17465 administered systemically, presented orally, and N17350 directed at…

Read MoreOnchilles Pharma Unveils AACR 2024 Preclinical Data: Promising Treatment Potential

Edgewood Oncology: Promising BTX-A51 Study Results in Liposarcoma Preclinical Models

Edgewood Oncology, a biotech company specializing in BTX-A51 treatments for hematologic malignancies and solid tumors, has revealed fresh preclinical findings. The study, conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School, explores BTX-A51’s potential in human liposarcoma (LPS). These…

Read MoreEdgewood Oncology: Promising BTX-A51 Study Results in Liposarcoma Preclinical Models